Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19079740 | 0.77 | SMN1; SMN2 (0.58) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079854 | 0.69 | PDE4D (0.67) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079869 | 0.69 | PDE4D (0.58) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079759 | 0.69 | PDE4D (0.74) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079868 | 0.68 | MAPT (0.61) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079863 | 0.67 | PDE4D (0.72) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079867 | 0.67 | PDE4D (0.58) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079743 | 0.67 | MAPT (0.67) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079741 | 0.67 | PDE4D (0.76) | PDE4DSMN1; SMN2TP53RXFP1MAPT | |
| SCHEMBL19079758 | 0.65 | PDE4D (0.76) | PDE4DSMN1; SMN2TP53RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | VANDERBILT UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190717-A1 | Compounds and Methods for Inhibition of Hedgehog Signaling and Phosphodiesterase | PDE4A, PDE4B, PDE7A | PDE4D 6/4885SMN1; SMN2 4025/4885TP53 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.